Can Mounjaro Cause Irregular Periods?

What the clinical data shows, and what it doesn't

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults on tirzepatide for 72 weeks and recorded a broad range of adverse events. Menstrual irregularity as a distinct category was not highlighted in the top-line safety reporting, which means it did not meet the threshold for a frequently reported adverse effect in that study population. That is not the same as saying it cannot happen.

What SURMOUNT-1 did confirm is that tirzepatide produces substantial average weight reductions, around 20–21% at the highest dose. Weight loss of that scale, achieved over months rather than years, significantly alters circulating oestrogen levels. Adipose tissue is an active site of oestrogen production; as fat mass falls, oestrogen output shifts, and that shift can disrupt the hypothalamic-pituitary-ovarian axis that governs the menstrual cycle. This is a well-documented physiological mechanism, not a speculative one. The NHS medicines page for tirzepatide advises patients to tell their doctor if they notice any unexpected changes in their health during treatment, which includes reproductive health.

So the honest clinical picture is this: Mounjaro itself is not proven to directly cause irregular periods through its pharmacological action on GIP and GLP-1 receptors. But the weight loss it produces almost certainly can, especially in the earlier months of treatment when changes are steepest.

How weight-related hormonal shifts affect periods

The relationship between body weight and menstrual regularity is not new science. Women who lose weight quickly (through any means) sometimes find that their periods become lighter, less frequent, or temporarily absent. The reverse is also true: weight gain is associated with heavier or more irregular cycles, often through a different hormonal pathway involving insulin and androgens.

Tirzepatide works partly by slowing gastric emptying and reducing appetite, which leads to a sustained caloric deficit. As the body composition changes, sex hormone-binding globulin levels typically rise, and free oestrogen falls. For some women, particularly those who were previously carrying significant excess weight, this can actually regularise a previously disrupted cycle, particularly for those with polycystic ovary syndrome (PCOS), where elevated insulin and androgen levels are part of the problem. For others, especially those whose hormonal baseline was already balanced, rapid loss can temporarily tip the cycle into an irregular pattern. Our detailed page on Mounjaro and periods covers this hormonal interplay in full.

Either outcome is plausible depending on the individual's starting point. This is exactly why a prescriber's assessment before and during treatment matters, a one-size statement does not fit the clinical reality.

The contraceptive pill: an important practical consideration

One area where the Mounjaro SmPC is explicit is oral contraception. Because tirzepatide slows gastric emptying, it can reduce the absorption of oral medicines taken at the same time, including the combined or progestogen-only pill. The advice from NHS guidance, backed by the MHRA, is clear: women using an oral contraceptive should add a non-oral method (such as condoms) for the first four weeks of starting Mounjaro and for four weeks after each dose increase. After that stabilisation window, the pill is expected to absorb normally again.

This matters practically. If a woman is relying solely on the pill during a dose-increase month (say, the step from 5mg to 7.5mg) she may have reduced contraceptive cover without realising it. Missing this interaction is one of the questions our clinical team covers during every treatment review. It is also worth knowing that semaglutide (Wegovy) does not carry the same evidence of pill absorption reduction, though taking any medication carefully remains good practice.

For a closer look at whether Mounjaro can stop periods entirely, that question is answered separately.

When to speak to a clinician about cycle changes on Mounjaro

Minor shifts in cycle timing or flow in the early weeks of treatment, while weight is changing quickly, are not automatically alarming. But some changes should not wait for the next routine check-in. Raise any of the following promptly with a prescriber or your GP: periods stopping entirely for more than two to three cycles; unusually heavy bleeding that is new; significant pelvic pain alongside a change in cycle; or any possibility of pregnancy, since Mounjaro is not recommended during pregnancy and should be stopped if pregnancy is confirmed.

The NHS England guidance on weight-management injections specifically recommends that women of childbearing potential discuss contraception with their prescriber before starting treatment. If you are using Mounjaro through a private service and a cycle change concerns you, contact the aftercare team rather than waiting. At nume, support is available seven days a week precisely for situations like this.

Questions about whether Mounjaro can trigger a period, or about heavier bleeding specifically, are covered in their own pages. If you are weighing up treatment options more broadly, patients in the East Midlands can find localised prescribing information on our Mounjaro Northampton page, and the free consultation is the right starting point, a GPhC-registered prescriber reviews every application the same day and can address reproductive health questions as part of that assessment.